|
1
|
GLOBOCAN 2012, . Estimated cancer
incidence, mortality and prevalence worldwide in 2012. Leyon: World
Health Organization; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxOctober
31–2018
|
|
2
|
Projected cancer statistics, 2017. Tokyo,
. Center for Cancer Control and Information Services, National
Cancer Center. https://ganjoho.jp/en/public/statistics/short_pred.htmlOctober
31–2018
|
|
3
|
Cancer statistics in Japan 2016. Tokyo, .
Center for Cancer Control and Information Services, National Cancer
Center. https://ganjoho.jp/en/professional/statistics/brochure/2016_en.htmlOctober
31–2018
|
|
4
|
NCCN Guidelines for treatment of cancer by
site, . Prostate Cancer. Fort Washington: National Comprehensive
Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfOctober
31–2018
|
|
5
|
Someya M, Hori M, Tateoka K, Nakata K,
Takagi M, Saito M, Hirokawa N, Hareyama M and Sakata K: Results and
DVH analysis of late rectal bleeding in patients treated with
3D-CRT or IMRT for localized prostate cancer. J Radiat Res (Tokyo).
56:122–127. 2015. View Article : Google Scholar
|
|
6
|
Cahlon O, Zelefsky MJ, Shippy A, Chan H,
Fuks Z, Yamada Y, Hunt M, Greenstein S and Amols H: Ultra-high dose
(86.4 Gy) IMRT for localized prostate cancer: Toxicity and
biochemical outcomes. Int J Radiat Oncol Biol Phys. 71:330–337.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamazaki H, Nakamura S, Nishimura T,
Yoshida K, Yoshioka Y, Koizumi M and Ogawa K: Transitioning from
conventional radiotherapy to intensity-modulated radiotherapy for
localized prostate cancer: Changing focus from rectal bleeding to
detailed quality of life analysis. J Radiat Res (Tokyo).
55:1033–1047. 2014. View Article : Google Scholar
|
|
8
|
Dolezel M, Odrazka K, Zouhar M, Vaculikova
M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J and Kovarik
J: Comparing morbidity and cancer control after 3D-conformal (70/74
Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate
cancer. Strahlenther Onkol. 191:338–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanaka H, Yamaguchi T, Hachiya K, Kamei S,
Ishihara S, Hayashi M, Ogawa S, Nishibori H, Goshima S and Matsuo
M: Treatment outcomes and late toxicities of intensity-modulated
radiation therapy for 1091 Japanese patients with localized
prostate cancer. Rep Pract Oncol Radiother. 23:28–33. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alicikus ZA, Yamada Y, Zhang Z, Pei X,
Hunt M, Kollmeier M, Cox B and Zelefsky MJ: Ten-year outcomes of
high-dose, intensity-modulated radiotherapy for localized prostate
cancer. Cancer. 117:1429–1437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bechis SK, Carroll PR and Cooperberg MR:
Impact of age at diagnosis on prostate cancer treatment and
survival. J Clin Oncol. 29:235–241. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu-Yao GL, Albertsen PC, Moore DF, Shih W,
Lin Y, DiPaola RS and Yao SL: Survival following primary androgen
deprivation therapy among men with localized prostate cancer. JAMA.
300:173–181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Japan ALTF: Tokyo. Ministry of Health,
Labour and Welfare, Japan, . 2016, http://www.mhlw.go.jp/english/database/db-hw/lifetb16/index.html
|
|
14
|
D'Amico AV, Whittington R, Malkowicz SB,
Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA,
Wein A, et al: Biochemical outcome after radical prostatectomy or
external beam radiation therapy for patients with clinically
localized prostate carcinoma in the prostate specific antigen era.
Cancer. 95:281–286. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roach M III, Hanks G, Thames H Jr,
Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining
biochemical failure following radiotherapy with or without hormonal
therapy in men with clinically localized prostate cancer:
Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int
J Radiat Oncol Biol Phys. 65:965–974. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Common Terminology Criteria for Adverse
Events (CTCAE) Version 4.0. Bethesda, . National Institutes of
Healths, Department of Health and Human Services. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfOctober
31–2018
|
|
17
|
Wilcox SW, Aherne NJ, McLachlan CS, McKay
MJ, Last AJ and Shakespeare TP: Is modern external beam
radiotherapy with androgen deprivation therapy still a viable
alternative for prostate cancer in an era of robotic surgery and
brachytherapy: A comparison of Australian series. J Med Imaging
Radiat Oncol. 59:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zelefsky MJ, Poon BY, Eastham J, Vickers
A, Pei X and Scardino PT: Longitudinal assessment of quality of
life after surgery, conformal brachytherapy, and
intensity-modulated radiation therapy for prostate cancer.
Radiother Oncol. 118:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayashi S, Tanaka H, Kajiura Y, Ohno Y and
Hoshi H: Stereotactic body radiotherapy for very elderly patients
(age, greater than or equal to 85 years) with stage I non-small
cell lung cancer. Radiat Oncol. 9:1382014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao YH, Demissie K, Shih W, Mehta AR,
Stein MN, Roberts CB, Dipaola RS and Lu-Yao GL: Contemporary risk
profile of prostate cancer in the United States. J Natl Cancer
Inst. 101:1280–1283. 2009. View Article : Google Scholar : PubMed/NCBI
|
